Abbisko Cayman Limited (HKG:2256)

Hong Kong · Delayed Price · Currency is HKD

9.03

+0.05 (0.56%)

Jun 18, 2026, 4:08 PM HKT

-9.25% (1Y)

Market Cap	6.43B +22.1%
Revenue (ttm)	681.17M +21.5%
Net Income	61.48M +95.2%
EPS	0.10 +121.1%
Shares Out	716.46M
PE Ratio	91.24
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,124,500
Open	8.88
Previous Close	8.98
Day's Range	8.66 - 9.23
52-Week Range	8.34 - 19.78
Beta	1.21
Analysts	Strong Buy
Price Target	22.95 (+154.15%)
Earnings Date	Aug 4, 2026

About Abbisko Cayman

Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocel... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 276

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2256

Full Company Profile

Financial Performance

In 2025, Abbisko Cayman's revenue was 612.12 million, an increase of 21.45% compared to the previous year's 503.99 million. Earnings were 55.25 million, an increase of 95.21%.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 9 analysts, the average rating for 2256 stock is "Strong Buy." The 12-month stock price target is $22.95, which is an increase of 154.15% from the latest price.

Price Target

$22.95

(154.15% upside)

Analyst Consensus: Strong Buy

Stock Forecasts